Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2003

View Archived Issues

Ganstigmine safe in patients with probable Alzheimer's disease

NSAIDs evaluated for slowing the progression of Alzheimer's disease

Low response rate for SU-5416 in refractory myeloproliferative disorders

Improved glycemic control reported for nateglinide plus rosiglitazone in type 2 diabetes

Apafant effective in UVB-induced dermatitis

Wyeth claims three series of ERbeta-selective estrogenic agents for arthritis, IBD, etc.

Plant extract with gastric antisecretory activity patented by Korean researchers

Novel bone antiresorptive agents covered by Sankyo patent

New tachykinin NK1 antagonists prepared and tested at Schering-Plough

Novo Nordisk scientists present new glucagon antagonists/inverse agonists in recent patent

Roche describes new inhibitors of MDM2/p53 interaction with utility in cancer

Novel protein kinase inhibitors in early development at Abbott

South Korean scientists report synthesis and biological evaluation of promising antitumor retinoid

Caspase-dependent cell-killing and TRAIL-sensitizing effects reported for estrogen derivative

Discovery of potent, orally active, irreversible Her-2 receptor tyrosine kinase inhibitor reported

A-409100, a second-generation FTase inhibitor with a promising preclinical profile

Selective chemotherapy with SDX-102 in MTAP-deficient tumors

Positive safety results emerge from phase I/II study of Theralux

4SC and Esteve broaden their research partnership

AMD-3100 granted orphan drug status for stem cell transplantation in cancer patients

Boehringer Ingelheim and Medivir sign agreement for MIV-310

FDA advisory panel to review Onyx for the treatment of certain neurovascular disorders

Roche SARS test now available

Curacyte discovers new antitumor agents

Antiangiogenic/antitumor VEGFR kinase inhibitor with an anthranilamide structure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...